Practically, the Food and Drug Administration accepted two Hdac inhibitors suberoylanilide hydroxamic acid (SAHA) and FK-228 for the treatment of cutaneous T-cell lymphoma, and several Hdac inhibitors are in phase I or II of clinical trials in cancer patients (Monneret 2005). The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.